Cinclus Pharma Holding AB (publ) (STO: CINPHA)
Sweden flag Sweden · Delayed Price · Currency is SEK
18.75
+0.05 (0.29%)
At close: Jan 20, 2025

Cinclus Pharma Holding AB Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Revenue
-5.9610.57---
Revenue Growth (YoY)
--43.63%----
Gross Profit
-5.9610.57---
Selling, General & Admin
35.7939.5664.1214.452.610.8
Research & Development
116.55166.68157.1869.8236.6922.02
Operating Expenses
151.81206.24221.384.2739.2922.82
Operating Income
-151.81-200.28-210.73-84.27-39.29-22.82
Interest Expense
--7.45-0.08-0.01--
Interest & Investment Income
4.813.031.18--0.06
Currency Exchange Gain (Loss)
-10.49-10.49-21.398.01-3.650.42
Other Non Operating Income (Expenses)
0.580.580000
Pretax Income
-156.91-214.61-231.01-76.27-42.94-22.33
Income Tax Expense
10.5118.06---
Net Income
-157.91-215.12-249.07-76.27-42.94-22.33
Net Income to Common
-157.91-215.12-249.07-76.27-42.94-22.33
Shares Outstanding (Basic)
322623210-
Shares Outstanding (Diluted)
322623210-
Shares Change (YoY)
38.66%13.81%9.26%8415.70%--
EPS (Basic)
-4.94-8.20-10.81-3.62-173.37-
EPS (Diluted)
-4.94-8.20-10.81-3.62-173.37-
Free Cash Flow
-162.88-209.19-192.08-75.48-39.47-23.17
Free Cash Flow Per Share
-5.10-7.98-8.33-3.58-159.37-
Gross Margin
-100.00%100.00%---
Operating Margin
--3360.98%-1993.45%---
Profit Margin
--3609.97%-2356.20%---
Free Cash Flow Margin
--3510.42%-1817.01%---
EBITDA
-151.7-200.25-210.69-84.26-39.28-22.8
D&A For EBITDA
0.110.030.040.010.010.02
EBIT
-151.81-200.28-210.73-84.27-39.29-22.82
Source: S&P Capital IQ. Standard template. Financial Sources.